The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Investors recently learned about undisclosed data from one of Amgen's clinical trials. The new information didn't look ...

Goldman Sachs analysts removed Amgen (AMGN) from the firm’s US Conviction List as part of its monthly update.Don't Miss our Black Friday ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Amgen's experimental drug MariTide helped overweight or obese patients lose up to 20% weight on average in a year-long ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Amgen Inc. shares fell the most in 23 years after its experimental obesity shot failed to significantly outperform rivals and ...

Since its establishment in 1990, the ABE program has now reached over 1 million students across 16 countries, helping to ...

Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.